675 studies (9 from unattributed sources) on Tirzepatide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
| Manufacturer | Batches | Avg purity | |
|---|---|---|---|
| Bfflist Amo | 247 | 99.61% | View COA → |
| Sry Labs | 207 | 99.55% | View COA → |
| Shanghai Sigma Audley Ssa | 140 | 99.56% | View COA → |
| Hk Peptides | 133 | 99.76% | View COA → |
| Allen Biotechnology Co Abc | 124 | 99.66% | View COA → |
| Planet Peptide | 105 | 99.76% | View COA → |
| Zlz Peptide | 94 | 99.72% | View COA → |
| GYC | 93 | 99.73% | View COA → |
Recent certificates: #27962 (99.94%) · #28001 (99.52%) · #30760 (99.98%) · #31566 (99.96%) · #42192 (99.69%) · #42719 (99.95%)
Manufacturers with published third-party certificates of analysis for Tirzepatide. Open a vendor to see every batch we've verified.
The pervasive and devastating impact of addiction, affecting billions globally and incurring significant health, social, and economic costs, underscores the critical need for innovative treatment strategies. Incretin-…
A deeper understanding of the precise mechanisms underlying beta-cell stress and identity failure is absolutely crucial for the development of novel, disease-modifying therapeutic strategies for type 2 diabetes. This …
This research highlights the critical need for a more personalized approach to semaglutide therapy, moving beyond average treatment effects. Identifying predictors for suboptimal response could enable clinicians to ta…
This study powerfully underscores the chronic nature of obesity and the significant challenge of weight regain following tirzepatide discontinuation, emphasizing that sustained pharmacological intervention may be nece…
This pooled analysis strongly suggests that Tirzepatide is a highly effective add-on therapy for patients with Type 2 Diabetes who are not achieving optimal glycemic control with basal insulin alone. The dual action a…
These findings are highly significant, as they demonstrate that Tirzepatide, a dual GLP-1/GIP receptor agonist, offers substantial benefits beyond glycemic control and weight loss, directly addressing critical cardiov…
This pilot study holds significant promise, as successful integration of weight management strategies could potentially improve treatment efficacy and long-term outcomes for endometrial cancer patients. If tirzepatide…
This pilot study is crucial for understanding Tirzepatide's potential as a targeted therapy for MASLD, a condition with limited effective treatment options. Positive findings could pave the way for larger, more defini…
Finding effective strategies to prevent weight regain after discontinuing GLP-1 agonists is critically important for long-term obesity management and patient well-being. This trial could provide evidence for new stand…
Understanding the unique pathophysiology of Normal-Weight Type 2 Diabetes (NWD) is crucial, as these individuals may not benefit from traditional weight-loss-focused interventions for T2D. This study's findings could …
This Phase II trial is significant because it addresses a critical unmet need for effective weight management in adult survivors of childhood Acute Lymphoblastic Leukemia (ALL), a group highly susceptible to cardiomet…
This trial is critically important because it addresses a significant gap in our understanding of how tirzepatide performs in a vulnerable and growing patient group. The findings could establish a new therapeutic opti…
This groundbreaking GLP-1 brain atlas provides a foundational neuroanatomical map, offering unprecedented insights into the diverse physiological roles of GLP-1 beyond its well-known glucose-lowering effects. By preci…
This research provides crucial insights into the genetic underpinnings of GLP-1 RA response, paving the way for personalized treatment strategies. By identifying individuals most likely to benefit or experience advers…
This real-world evidence suggests that Tirzepatide could be a safe and effective therapeutic option for managing obesity and type 2 diabetes in kidney transplant recipients, a population often excluded from major clin…
This study addresses a critical need for practical, accessible dietary recommendations to complement GLP-1 RA therapy, potentially enhancing patient outcomes beyond just weight loss. If successful, it could provide a …
This study is pivotal as it explores a novel, multimodal approach to pre-surgical optimization for a high-risk patient population. If successful, the findings could revolutionize the standard of care for obese patient…
This study provides initial evidence that combining LY3457263 with tirzepatide could represent a more potent and effective strategy for treating obesity than existing monotherapies. The favorable safety profile and en…
This clinical trial is profoundly significant as it explores a novel and promising therapeutic approach for ADPKD, a disease with limited treatment options and a high burden on patients. If successful, this research c…
If successful, this pilot study could pave the way for a novel pre-surgical intervention to improve outcomes for prostate cancer patients. Demonstrating the feasibility of tirzepatide-assisted weight loss could lead t…
Had it been completed, this registry would have provided an invaluable real-world dataset for understanding the long-term trajectory of obesity and metabolic diseases, offering insights into how these conditions evolv…
If tirzepatide proves safe and effective, it could represent a significant therapeutic advancement for individuals with Type 1 Diabetes who struggle with obesity or overweight. Currently, there are limited pharmacolog…
This case report is crucial as it highlights a potential, albeit rare, adverse event associated with Tirzepatide that could have significant implications for patient safety and clinical practice. Given the widespread …
This study provides robust real-world evidence supporting the favorable cardiovascular safety profile of tirzepatide, particularly concerning heart failure and arrhythmias, in a diverse patient population. The consist…
This study provides crucial evidence that early intervention with tirzepatide and semaglutide can significantly mitigate the progression of atherosclerosis, a leading cause of morbidity and mortality worldwide. The ob…
This case report provides compelling preliminary evidence suggesting a novel therapeutic avenue for Tirzepatide beyond its established metabolic indications. The observed improvements in autonomic dysfunction and POTS…
This case highlights a rare but potentially life-threatening adverse event associated with Tirzepatide use, particularly in individuals without pre-existing diabetes. It underscores the critical importance of educatin…
This real-world evidence strongly reinforces the efficacy and safety of Tirzepatide for managing Type 2 Diabetes and associated metabolic abnormalities in a broader, more diverse patient population than typically seen…
The initiation of this Phase IV trial is a significant step, as it explores a novel therapeutic avenue for Idiopathic Intracranial Hypertension (IIH), a condition with limited effective treatments. Tirzepatide, known …
The finding that tirzepatide pharmacokinetics are not significantly altered by renal impairment is highly significant. This suggests that patients with kidney disease, including those with end-stage renal disease (ESR…
This research holds significant promise for a population in dire need of improved treatment options, as patients with schizophrenia and AUD face unique challenges and poorer prognoses. If successful, this study could …
This study is critical because it directly addresses a common clinical scenario: how to optimize treatment for Type 2 Diabetes patients who may not be achieving their goals on existing GLP-1 RA therapy. The expected s…
This trial represents a paradigm shift in Type 1 Diabetes management, potentially transforming daily life for millions by simplifying insulin delivery and reducing mental burden. If successful, tirzepatide could enabl…
Obesity-related male infertility is a growing concern, and current treatments often lack sustained efficacy or adherence. This trial holds the potential to identify a novel and effective pharmacological intervention f…
This case report holds significant clinical importance as it expands the known adverse event profile of Tirzepatide, alerting clinicians to the possibility of drug-induced liver injury. While such events are rare, rec…
This real-world comparative study provides crucial insights into the relative effectiveness of leading weight loss medications outside of controlled clinical trials. The findings strongly support Tirzepatide's superio…
This study provides critical early insights into the potential cardiovascular protective effects of Tirzepatide, even before the official results of SURPASS-CVOT are released. The predicted 23% MACE reduction is highl…
While specific numerical outcomes from this completed trial (NCT03882970) are not detailed in the provided record, the study's primary objective was to demonstrate the superior efficacy of tirzepatide in improving gly…
This research holds significant promise as tirzepatide could represent an innovative approach to effectively induce weight loss and inhibit tumor growth in obesity-driven endometrial cancer. Given the strong link betw…
The successful integration of Tirzepatide into OUD treatment could represent a paradigm shift in how we manage this complex disorder, offering a much-needed adjunctive therapy beyond current standards. Given Tirzepati…
As an active study (NCT07417618) not yet recruiting, specific results are not available; however, based on existing clinical trial data and the known mechanisms of these drugs, the study is expected to reveal signific…
Free, no account — handy when you're working with Tirzepatide.